Edda F Spiekerkoetter, MD
Pulmonary Disease · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Spiekerkoetter’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A109112 · Current
Licensed to practise in California · since 2009 · expires 2027-07-31 · Albert-Ludwigs-University of Freiburg Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$12,078
Medicare paid this office $12,078 for 69 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 17 | $2,022 | $88 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 20 | $1,232 | $44 |
Who their Medicare patients are
69 Original Medicare patients in 2024. Average age 70 · Women 68% · Also on Medicaid 33% · Health risk score 2.30. Above the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Heart failure 62% · Chronic kidney disease 51% · COPD 39% · Diabetes 36% · Atrial fibrillation 36% · Coronary heart disease 33% · Depression 29%.
The office billed $51,167, Medicare allowed $15,641 and paid $12,078; for 138 services of 16 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 69 | 138 | 70 | 2.30 | $51,167 | $12,078 |
| 2023 | 44 | 116 | 65 | 2.62 | $45,021 | $10,204 |
| 2022 | 63 | 156 | 69 | 2.36 | $58,853 | $14,184 |
| 2021 | 65 | 170 | 69 | 2.40 | $89,113 | $18,220 |
| 2020 | 60 | 153 | 67 | 2.90 | $63,685 | $13,215 |
| 2019 | 64 | 159 | 70 | 2.98 | $48,124 | $13,985 |
| 2018 | 55 | 103 | 70 | 2.69 | $18,353 | $7,413 |
| 2017 | 69 | 167 | 67 | 2.93 | $37,847 | $11,286 |
| 2016 | 63 | 147 | 68 | 2.50 | $34,250 | $10,051 |
| 2015 | 89 | 222 | 68 | 2.70 | $44,683 | $13,734 |
| 2014 | 74 | 177 | 67 | 2.32 | $45,873 | $13,582 |
| 2013 | 77 | 203 | 67 | 2.27 | $48,198 | $14,538 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $2,991 | $73 |
2022: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $3,463 | $62 |
| Return visit (30+ min) | 19 | $2,345 | $84 |
| Long return visit (40+ min) | 12 | $1,669 | $128 |
2021: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $3,137 | $67 |
| Return visit (30+ min) | 16 | $2,413 | $97 |
| Short return visit (20+ min) | 13 | $859 | $66 |
2020: 4 services
| Long return visit (40+ min) | 15 | $1,986 | $105 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,958 | $65 |
| Return visit (30+ min) | 17 | $1,490 | $74 |
| Short return visit (20+ min) | 11 | $594 | $46 |
2019: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $2,904 | $66 |
| Return visit (30+ min) | 20 | $1,978 | $71 |
| Long return visit (40+ min) | 14 | $1,674 | $98 |
| Short return visit (20+ min) | 15 | $743 | $44 |
2018: 2 services
| Return visit (30+ min) | 23 | $1,978 | $71 |
| Short return visit (20+ min) | 20 | $1,106 | $46 |
2017: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $2,267 | $65 |
| Short return visit (20+ min) | 33 | $2,115 | $44 |
| Return visit (30+ min) | 13 | $1,340 | $71 |
2016: 3 services
| Short return visit (20+ min) | 35 | $2,142 | $46 |
| Return visit (30+ min) | 22 | $1,783 | $61 |
| Long return visit (40+ min) | 12 | $1,346 | $90 |
2015: 6 services
| Long return visit (40+ min) | 38 | $4,798 | $92 |
| Return visit (30+ min) | 40 | $3,887 | $66 |
| New patient visit (60+ min) | 11 | $1,601 | $146 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 20 | $236 | $12 |
| Test to determine lung volumes using sensors | 18 | $200 | $11 |
| Test to examine how well the lungs exchange gases | 21 | $172 | $8 |
2014: 2 services
| Long return visit (40+ min) | 35 | $5,479 | $93 |
| Return visit (30+ min) | 21 | $2,341 | $67 |
2013: 6 services
| Long return visit (40+ min) | 38 | $6,265 | $91 |
| New patient visit (60+ min) | 18 | $2,614 | $145 |
| Return visit (30+ min) | 16 | $1,167 | $61 |
| Test to examine how well the lungs exchange gases | 20 | $170 | $9 |
| Test to determine lung volumes using sensors | 13 | $151 | $12 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 13 | $150 | $12 |
Drugs they prescribed that Part D paid
$1,298,340
Pharmacies billed $1,298,340 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 330) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
238 generic and 92 brand-name prescriptions · $1,298,340 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Winrevair | 20 | $278,698 | $13,935 |
| Opsumit | 17 | $217,246 | $12,779 |
| Adempas | 13 | $185,686 | $14,284 |
| Letairis | 13 | $153,580 | $11,814 |
| Ambrisentan | 52 | $152,512 | $2,933 |
See all 12 drugs
| Winrevair | 20 | $278,698 | $13,935 |
| Opsumit | 17 | $217,246 | $12,779 |
| Adempas | 13 | $185,686 | $14,284 |
| Letairis | 13 | $153,580 | $11,814 |
| Ambrisentan | 52 | $152,512 | $2,933 |
| Sildenafil Citrate | 75 | $41,325 | $551 |
| Tadalafil | 42 | $38,779 | $923 |
| Bosentan | 11 | $13,718 | $1,247 |
| Eliquis | 12 | $10,736 | $895 |
| Potassium Chloride | 18 | $701 | $39 |
| Bumetanide | 15 | $669 | $45 |
| Furosemide | 20 | $141 | $7 |
Year by year
| 2024 | 330 | 26 | 0% (0) | 28% | $1,298,340 |
| 2023 | 276 | 23 | 0% (0) | 22% | $1,111,606 |
| 2022 | 229 | 28 | 0% (0) | 28% | $859,065 |
| 2021 | 196 | 24 | 0% (0) | None | $709,412 |
| 2020 | 307 | 28 | 0% (0) | 25% | $989,215 |
| 2019 | 332 | 29 | 0% (0) | 33% | $1,192,834 |
| 2018 | 332 | 28 | 0% (0) | 45% | $840,293 |
| 2017 | 384 | 34 | 0% (0) | 49% | $1,097,590 |
| 2016 | 287 | 31 | 0% (0) | 62% | $914,184 |
| 2015 | 279 | 27 | 0% (0) | 59% | $574,468 |
| 2014 | 226 | 28 | 0% (0) | None | $267,062 |
| 2013 | 228 | 29 | None | 30% | $171,426 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Ambrisentan | 43 | $292,741 | $6,808 |
| Opsumit | 21 | $271,277 | $12,918 |
| Adempas | 12 | $161,701 | $13,475 |
| Bosentan | 11 | $85,120 | $7,738 |
| Tadalafil | 27 | $61,461 | $2,276 |
| Sildenafil Citrate | 88 | $58,635 | $666 |
| Potassium Chloride | 15 | $1,242 | $83 |
| Furosemide | 17 | $245 | $14 |
2022: 9 drugs
| Uptravi | 11 | $239,021 | $21,729 |
| Adempas | 12 | $152,546 | $12,712 |
| Opsumit | 12 | $124,876 | $10,406 |
| Ambrisentan | 35 | $107,074 | $3,059 |
| Bosentan | 11 | $71,626 | $6,511 |
| Sildenafil Citrate | 54 | $35,527 | $658 |
| Tadalafil | 13 | $29,504 | $2,270 |
| Trelegy Ellipta | 12 | $7,949 | $662 |
| Furosemide | 17 | $147 | $9 |
2021: 8 drugs
| Uptravi | 11 | $213,685 | $19,426 |
| Adempas | 12 | $143,915 | $11,993 |
| Opsumit | 13 | $139,846 | $10,757 |
| Ambrisentan | 28 | $63,151 | $2,255 |
| Sildenafil Citrate | 47 | $27,196 | $579 |
| Tadalafil | 17 | $24,375 | $1,434 |
| Spiriva Respimat | 11 | $5,213 | $474 |
| Furosemide | 12 | $99 | $8 |
2020: 8 drugs
| Uptravi | 16 | $321,382 | $20,086 |
| Opsumit | 17 | $166,074 | $9,769 |
| Ambrisentan | 51 | $141,791 | $2,780 |
| Bosentan | 11 | $73,818 | $6,711 |
| Sildenafil Citrate | 92 | $32,845 | $357 |
| Spironolactone | 17 | $446 | $26 |
| Furosemide | 33 | $258 | $8 |
| Pantoprazole | 12 | $204 | $17 |
2019: 7 drugs
| Opsumit | 36 | $365,734 | $10,159 |
| Letairis | 38 | $359,891 | $9,471 |
| Ambrisentan | 26 | $99,051 | $3,810 |
| Alyq | 11 | $43,948 | $3,995 |
| Sildenafil Citrate | 108 | $17,063 | $158 |
| Furosemide | 36 | $383 | $11 |
| Spironolactone | 15 | $316 | $21 |
2018: 9 drugs
| Letairis | 37 | $362,327 | $9,793 |
| Opsumit | 34 | $313,932 | $9,233 |
| Adcirca | 11 | $58,694 | $5,336 |
| Sildenafil | 112 | $43,745 | $391 |
| Spiriva | 14 | $8,070 | $576 |
| Bumetanide | 13 | $1,818 | $140 |
| Potassium Chloride | 11 | $514 | $47 |
| Spironolactone | 22 | $501 | $23 |
| Furosemide | 34 | $192 | $6 |
2017: 7 drugs
| Opsumit | 51 | $441,216 | $8,651 |
| Letairis | 40 | $379,598 | $9,490 |
| Adcirca | 22 | $95,308 | $4,332 |
| Sildenafil | 117 | $48,995 | $419 |
| Bumetanide | 16 | $916 | $57 |
| Spironolactone | 26 | $476 | $18 |
| Furosemide | 48 | $188 | $4 |
2016: 7 drugs
| Opsumit | 64 | $497,489 | $7,773 |
| Orenitram Er | 25 | $129,154 | $5,166 |
| Adcirca | 37 | $117,891 | $3,186 |
| Letairis | 12 | $107,453 | $8,954 |
| Sildenafil | 65 | $32,688 | $503 |
| Spironolactone | 14 | $198 | $14 |
| Furosemide | 23 | $135 | $6 |
2015: 8 drugs
| Orenitram Er | 37 | $195,318 | $5,279 |
| Opsumit | 26 | $191,327 | $7,359 |
| Adcirca | 55 | $137,566 | $2,501 |
| Edecrin | 11 | $19,854 | $1,805 |
| Sildenafil | 40 | $19,466 | $487 |
| Potassium Chloride | 17 | $710 | $42 |
| Furosemide | 32 | $291 | $9 |
| Levothyroxine | 12 | $196 | $16 |
2014: 6 drugs
| Opsumit | 20 | $144,243 | $7,212 |
| Adcirca | 49 | $96,393 | $1,967 |
| Sildenafil | 20 | $9,176 | $459 |
| Potassium Chloride | 14 | $560 | $40 |
| Furosemide | 27 | $284 | $11 |
| Spironolactone | 16 | $146 | $9 |
2013: 5 drugs
| Sildenafil | 30 | $86,722 | $2,891 |
| Adcirca | 21 | $50,179 | $2,389 |
| Spironolactone | 25 | $387 | $15 |
| Furosemide | 34 | $212 | $6 |
| Digox | 16 | $162 | $10 |
Money from drug and device companies
$1,313 in 2025
| 2025 | 1 | 9 | None | $1,313 |
| 2021 | 1 | 1 | None | $21 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merck Sharp & Dohme | Winrevair | $1,313 | 9 payments
|
See all 9 published payments
| Merck Sharp & Dohme | Meals · 2025-11-15 | Winrevair | $48 |
| Merck Sharp & Dohme | Meals · 2025-11-15 | Winrevair | $35 |
| Merck Sharp & Dohme | Travel · 2025-11-14 | Winrevair | $256 |
| Merck Sharp & Dohme | Meals · 2025-11-14 | Winrevair | $48 |
| Merck Sharp & Dohme | Meals · 2025-11-14 | Winrevair | $48 |
| Merck Sharp & Dohme | Meals · 2025-11-14 | Winrevair | $100 |
| Merck Sharp & Dohme | Meals · 2025-11-14 | Winrevair | $35 |
| Merck Sharp & Dohme | Travel · 2025-11-13 | Winrevair | $486 |
| Merck Sharp & Dohme | Travel · 2025-11-13 | Winrevair | $256 |
See earlier years (2021)
2021: $21
| Sunovion Pharmaceuticals | Gemtesa | $21 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1184857211
- Licence
- CA A109112California A109112: Current · expires 2027-07-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Federal specialty code 207RC0200X (207RC0200X)
- Mailing address
- 335 Waverley St, Menlo Park, CA, 94025
- NPI first listed
- 2009-08-24
- NPI last updated
- 2009-08-25
This is when the NPI record was last certified, not a medical board exam.